Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Significant Decrease in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 18,363 shares, a decline of 27.8% from the January 29th total of 25,448 shares. Currently, 1.4% of the company’s stock are short sold. Based on an average daily volume of 26,672 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily volume of 26,672 shares, the days-to-cover ratio is presently 0.7 days. Currently, 1.4% of the company’s stock are short sold.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. McKinley Carter Wealth Services Inc. bought a new stake in shares of Sonoma Pharmaceuticals during the 4th quarter valued at $41,000. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals in the 2nd quarter worth $96,000. Finally, DRW Securities LLC boosted its stake in shares of Sonoma Pharmaceuticals by 257.2% in the fourth quarter. DRW Securities LLC now owns 60,977 shares of the company’s stock worth $222,000 after acquiring an additional 43,907 shares during the period. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Trading Up 1.2%

SNOA stock traded up $0.04 on Monday, hitting $2.94. The company had a trading volume of 1,020 shares, compared to its average volume of 14,665. Sonoma Pharmaceuticals has a 12-month low of $1.75 and a 12-month high of $6.92. The stock has a market cap of $5.08 million, a price-to-earnings ratio of -1.44 and a beta of 1.65. The stock’s 50-day simple moving average is $3.27 and its 200 day simple moving average is $3.75.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Tuesday, February 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative net margin of 19.04% and a negative return on equity of 42.56%. The company had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $5.47 million. Research analysts forecast that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.